The David B. Frohnmayer Early Investigator Award was inaugurated in 2015, months after FARF co-founder Dave Frohnmayer passed away. One of his most salient leadership traits was his ability to recognize talent in others and inspire them to solve important...
Announcements
Mutations in 23 Fanconi anemia (FA) genes cause defects in DNA repair, which leads to chromosome instability, bone marrow failure, malformations, and susceptibility to cancer. The most well-described role of FA genes in DNA repair is known as the “canonical”...
Announcements
What motivates me to work on FA: The patients and the families; that is clear for me. When I was an undergraduate student, I realized that I would like to work in genetic engineering to correct inherited disorders, but I...
Announcements
New approaches are needed for both prevention and treatment of squamous cell carcinoma (SCC) in patients with FA - approaches that have fewer and less severe side effects than chemotherapy and radiation therapy. The purpose of this Phase 2 study...
Announcements
Following a successful bid for an international support grant offed by FARF, Fanconi Hope in the UK and Fanconi Anemie Werkgroep of the VOKK (Dutch Parents, Children and Cancer Association), Netherlands, are setting up a new group called FA Europe. This will...
Announcements
Why gene therapy? We know that Fanconi anemia (FA) is caused by defects in any one of 23 different genes called “FANC” genes. If we could somehow repair or replace these defective FANC genes, we could treat or prevent FA...
Announcements
